• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endoscopy International Open >Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study
【24h】

Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study

机译：抗回流粘膜消融（ARMA）作为胃食管反流难以解决质子泵抑制剂的新治疗方法：试验研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background?The incidence of proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) has been increasing. While surgical intervention with Laparoscopic Nissen Fundoplication remains the gold standard, less invasive anti-reflux interventions are desired. We have developed a minimally invasive anti-reflux mucosal ablation (ARMA) treatment. Herein, we report its technical details and describe its feasibility, safety, and efficacy in PPI-refractory GERD. Methods?We conducted a prospective single-center single-arm interventional trial evaluating the outcome of ARMA in 12 patients with PPI-refractory GERD. GERD-Health Related Quality of Life Questionnaire (GERD-HRQL) evaluation, Frequency Scale for the Symptoms of GERD (FSSG) assessment, and impedance-pH monitoring were performed at baseline and at 2 months post-ARMA. Results?A total of 12 patients underwent ARMA with a median follow-up duration of 9 months (range: 6?–?14 months). Median GERD-HRQL score significantly improved from 30.5 to 12 (P?=?0.002); median FSSG score significantly improved from 25 to 10.5 (P?=?0.002), and median DeMeester score decreased from 33.5 to 2.8 (P?=?0.049) at 2 months follow-up.?No immediate complications were observed. Conclusion?Our pilot study has shown that ARMA, a new endoscopic treatment for PPI-refractory GERD, is simple, safe, and improves GERD-related symptoms and objective acid reflux parameters. sup*/sup The abstract of an earlier version of this article was presented at Digestive Disease Week 2019 (May 2019; San Diego, CA, USA).
机译：背景？质子泵抑制剂（PPI）的发病率 - 重新治疗胃食管反流疾病（GERD）一直在增加。虽然用腹腔镜尼森基金专用的外科介入仍然是金标准，但需要较少的侵入性抗反流性干预措施。我们开发了一种微创抗反动粘膜消融（ARMA）处理。在此，我们报告其技术细节并描述了PPI-Remctory GERD中的可行性，安全性和疗效。方法？我们进行了一项潜在的单中心单臂介入试验，评估了12例PPI-Remctory GERD患者ARMA的结果。 GERD-Health相关的生活质量问卷（GERD-HRQL）评估，GERD（FSSG）评估症状的频率规模和阻抗-PH监测在基线和arma后2个月进行。结果？共有12名患者接受了arma，中位后续时间为9个月（范围：6？ - ？14个月）。中位数GERD-HRQL得分从30.5到12（p？= 0.002）显着提高;中位FSSG得分从25到10.5（p？= 0.002）显着提高（p？= 0.002），中位赛奈斯特评分从33.5到2.8（p？= 0.049）在2个月内减少，遵守立即并发症。结论？我们的试验研究表明，ARMA是PPI-Remctory GERD的新内窥镜治疗，简单，安全，改善了GERD相关的症状和客观酸反流参数。 * 本文早期版本的摘要是在2019年消化疾病周（2019年5月;圣地亚哥，CA，USA）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号